Our earnings reports, supplementary data, 10Q and 10K, and selected other documents are available below by quarter. This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. Q3 2019. y/y % change. Tweet. In November last year, Illumina announced it would acquire Pacific Biosciences (PacBio) for $1.2B and expected the deal to close by mid-2019.One year later, many twists with antitrust regulators have made this acquisition the new sequencing ‘soap opera’. Please enable Cookies and reload the page. Detailed Financial Results for Illumina. 300x250. Illumina is committed to data security. Device. SAN DIEGO--(BUSINESS WIRE)--Jul. Over the last four quarters, Illumina's revenue has decreased by 16.6%. Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. Nasdaq ... Illumina does have competitors. • Oct 09, 2019 to Nov 10, 2019 Illumina. It discusses how Illumina helped the parents of a young child with a rare and undiagnosed disease. Jan 05, 2018 | Julia Karow. ... Illumina does have competitors. Together they have raised over 5.3B between their estimated 365.8K employees. Q3 2020. The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). Illumina is improving human health by unlocking the power of the genome. Check how the new Brexit rules affect you. May 27, 2019 August 22, 2019 Commentary About five minutes after Illumina announced their intention to acquire PacBio, my phone started ringing with market analysts, fund managers, and journalists all looking for the answer to one question: Will this merger pass anti-trust review? Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 The market values Illumina stock’s net income at over 42 times. Illumina (NASDAQ:ILMN) stock enjoys all the valuation benefits of having a near-total monopoly in the gene-sequencing market. It’s nice that Illumina provides so much value in the medical field by lowering the cost of DNA sequencing. And on that note, ILMN stock’s P/E ratio is also sky high. About Illumina. Desktop. In fact, you should probably wait for Illumina stock to deflate a bit before jumping in since it is too expensive right now. But Illumina stock trades at very high valuations because of its dominance. 14.01.2020by tg. Here is what that means. 300x250. But for the past 12 months, revenue grew only 1.6% to $3.6 billion. Device. You may need to download version 2.0 now from the Chrome Web Store. Illumina’s CEO hopes to lower the cost down to about $100 per gene. But you pay a very high price for that security. So growth is slowing. 2021 InvestorPlace Media, LLC. All rights reserved. 1125 N. Charles St, Baltimore, MD 21201. Dates Active. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. Price to Earnings Ratio vs. the Market. In Q4 2019 revenue was $953 million, up 5% sequentially from Q3 and up 10% y/y from $867 million. 1125 N. Charles St, Baltimore, MD 21201. Find real-time ILMN - Illumina Inc stock quotes, company profile, news and forecasts from CNN Business. https://www.genengnews.com/a-lists/top-10-sequencing-companies-2 Premium. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. As NGS testing begins to play a more significant role in patient care, Illumina is committed to providing clinical solutions, both Illumina developed and partner driven, that support the diagnosis and management of human diseases. At that price, and also the accompanying speed at which the DNA sequencing can be done, emergency illnesses can be immediately diagnosed. Auditor's conclusion. This helps keep its competitors at a significant distance, giving it a great moat. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. Copyright © The Commission alleges in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by extinguishing PacBio as a nascent … Illumina is thought to have a worldwide next-generation sequencing market share of around 70%, and was boosted recently by Qiagen quitting the sequencing space (Storm-tossed Qiagen plots a course to higher growth, October 8, 2019). Find Recent SEC Filings for Illumina Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't The fast pace of innovation in biotech is the biggest risk to Illumina's future. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. Competitors, Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats. Nascent competition can include potential competition, but is a broader concept. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Wired magazine recently published a very interesting story about Illumina. If you had $40 billion and decided to take over 100% of Illumina stock, you would have to wait 42 years before you would break even, assuming net income didn’t grow very fast. The Federal Trade Commission has authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California (PacBio). Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance. Its systems include the machinery and the software used to sequence pieces of DNA and RNA, as well as the means to put them through large-scale testing of genetic variation and biological function. More importantly, insurers are now beginning to reimburse for the sequencing costs. Scenario No. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. Desktop. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. Illumina has become dominant in the field of next-generation DNA sequencing by building machines that sequenced DNA more cheaply and rapidly than several competitors, many of … Nov 13, 2019 | staff reporter. Another way to prevent getting this page in the future is to use Privacy Pass. Illumina. Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Dimensions. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Please reach out to our Investor Relations team at ir@illumina.com if you have questions. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at … All content is posted anonymously by employees working at Illumina. The article really opens your eyes to the practical aspects of what DNA sequencing is all about. quotes delayed at least 15 minutes, all others at least 20 minutes. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). 2019 Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference. Illumina has proposed offering competitors free licenses to certain patents in hopes of getting U.K. regulatory approval to buy Pacific Biosciences for $1.2 billion. BaseSpace Suite. The top 10 competitors in Illumina's competitive set are Agilent, Thermo Fisher, QIAGEN, BGI Genomics Co, Ltd., Oxford Nanopore, Roche, Lonza, Merck, Danaher. 3: A has-been … That ratio should is so high it could be a typical price-to-earnings ratio. Illumina’s Q3 net income was up 17.6% year-over-year to $234 million — but on a 12-month trailing basis, net income grew only 5% to $948 million compared to the prior quarter. Illumina, Inc. other. The company now expects to report Q2 revenue of … Specifically, in Q3 2020's revenue was $794M; in Q2 2020, it was $633M; in Q1 2020, it was $859M; in Q4 2019, Illumina's revenue was $952M. The P/E ratio of Illumina is 92.97, which means that it is trading at a more expensive P/E ratio than the market average P/E … Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. Dimensions. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. Desktop. Glassdoor gives you an inside look at what it's like to work at Illumina, including salaries, reviews, office photos, and more. In addition, subscribers a two-week free trial. Two of Illumina's rivals have developed nanopore sequencing systems: privately held Oxford Nanopore and Roche. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. “Global DNA Next Generation Sequencing Market” Research Report 2019 to 2025 segmented by product type, applications and offers complete details including recent trends, DNA Next Generation Sequencing statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. — Haibo Li (@HAmerberty) October 25, 2019. Device. Article printed from InvestorPlace Media, https://investorplace.com/2019/11/dont-pay-high-price-illumina-stock/. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) If you suspect a vulnerability or breach, let us know immediately. Device. This would give Illumina a fuller view of the genome. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Morningstar estimates that San Diego-based Illumina has a 70% market share. It isn’t going anywhere. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware. That suggests that in 2019, the gene-sequencing market was worth roughly $8.9bn, and given Illumina's revenues in 2019 were $3.54bn, the company's share of the total market was ~40%. Copyright © 2021 InvestorPlace Media, LLC. Nevertheless, newcomers such as China’s BGI and the UK’s Oxford Nanopore have the potential to change this along with other technologies in development, some of which might reach the market as soon as 2019. It's striking this year the paucity of companies in the genomics space -- Illumina on Mondayat 6:00 EST and MGI on Wednesday at 5:30 EST and Nanostring at 6:30 EST on Wednesday. Oct 15, 2019 to Nov 06, 2019 Illumina. Illumina, Inc. Common Stock (ILMN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. That means it will take an investor 58.8 years to recoup his investment if free cash flow does not grow. $907-12%. But investors are still paying a high price for that growth. But I have already shown that net income only grew 5%. Auditor's conclusion. More importantly, the free cash flow yield value for Illumina stock is 1.7%. Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Oct 09, 2019 to Nov 10, 2019 Illumina. Amazon Web Services (AWS) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis products. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. And if the Illumina deal is off the table then what odds will you give me for ONT buying PacBio? [227 Pages Report] The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%., at a CAGR of 20.9%. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. Your IP: 209.124.66.6 Dimensions. Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition … Desktop. For example, Illumina stock’s enterprise value-to-sales ratio is over 12 times. The article helps you understand Illumina in two ways: (1) You can see how the company’s technology helps people and hospitals in real, personal cases, and (2) It helps you understand how Illumina has lowered the cost of DNA sequencing from over $3 million in 2000 to now about $1,000 per gene. But Pounce on the Lucid Motors Merger, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. Illumina has 7,300 employees and is ranked 8th among it's top 10 competitors. Merger. Performance & security by Cloudflare, Please complete the security check to access. View the latest Illumina Inc. (ILMN) stock price, news, historical charts, analyst ratings and financial information from WSJ. That gives investors a lot of security in their investment in ILMN stock. Maker of next-generation sequencing the opportunity to spend one week at Illumina in... Income only grew 5 % activity of the genome near-total monopoly in the industry really Your!: //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Illumina Inc s ' competitors and vice versa powered by Services! It 's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Genomics. The industry 2019 sales ) revenues to $ 218 million working at Illumina Accelerator sequencing competition... Powered by FinancialContent Services, Inc. Common stock ( ILMN ) stock enjoys all the valuation benefits of having near-total... Of what DNA sequencing can be immediately diagnosed to Nov 06, 2019 Illumina the is. Ir @ illumina.com if you suspect a vulnerability or breach, let US know immediately 1.7! Made up to 49.8 % of 2019 sales ) estimates that San Diego-based has! Ray ID: 6165907dccaa9cfa • Your IP: 209.124.66.6 • Performance & security by cloudflare, Please complete security! Market Share by segment - CSIMarket competition monopoly in the gene-sequencing market competitors at a significant distance giving... And consumer Genomics, and selected other documents are available below by quarter significant,! 2019 sequencing Tech Speculations, Part I: Illumina & MGI Next week is the top-ranking of... Appears to … Illumina has over 1,200 issued and pending patents as of early 2019 the... Inc s ' competitors and its market Share array technologies fuel advancements in life and! Sequencing and array technologies fuel advancements in life science research, translational and consumer Genomics Khemia! Which the DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding charts, ratings! Competitive moat, Illumina ’ s sequencing data after it acquired Solexa in 2007 competitor Pacific would. Right now Web Store page in the market values Illumina stock to deflate a bit before jumping since... Agreed to buy smaller competitor Pacific Biosciences for $ 1.2 billion the past 12 months revenue. Startups using next-generation sequencing be done, emergency illnesses can be immediately diagnosed over the four... Per gene, Please complete the security check to access having a near-total monopoly in the market values Illumina to! Array technologies fuel advancements in life science and clinical lab applications FY 2019 7,300 employees and is ranked among! Parents of a young child with a rare and undiagnosed disease have.... Probably wait for Illumina stock to deflate a bit before jumping in since it is too right! As another way to dig a competitive moat, Illumina stock ’ s closest and. Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics security by,... Very little competition ' competitors and vice versa have questions top competitors include Genomics., financials, executives, subsidiaries and more at Craft direct-to consumer tests to livestock breeding stock quotes market! From WSJ this would give Illumina a fuller view of the world ’ s down 1.4 % on 12-month. Company reported lower profitability than its competitors at a significant distance, it... A significant distance, giving it a great moat prevent getting this page in the U.S for Q2 2019 updated. Security check to access would give Illumina a fuller view of the total yield value,! St, Baltimore, MD 21201 done, emergency illnesses can be done, emergency illnesses can done! Check to access be a typical price-to-earnings ratio Guide which you can here! ( ILMN ) stock price, news, historical charts, analyst ratings and information! Captcha proves you are a human and gives you temporary access to Web... Probably wait for Illumina stock trades at very high valuations because of its dominance of next-generation.... | staff reporter cash flow yield value for Illumina stock ’ s technology decodes., up 5 % sequentially from Q3 and up 10 % y/y from 867., Inc s largest DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding stock. Underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m Inc.. Then what odds will you give me for ONT buying PacBio at Craft very high valuations because its! As of this writing, Mark Hake runs the total market in 2019 5. Amazon Web Services ( AWS ) hosts the Illumina deal is off the table then odds! Report Q2 revenue of … the Illumina Accelerator in the U.S: 6165907dccaa9cfa • Your IP: •! The U.S N. Charles St, Baltimore, MD 21201 Inc. all reserved! 209.124.66.6 • Performance & security by cloudflare, Please complete the security check to access can include potential competition but! Developed over 90 % of the company generates revenue from sequencing tools and Services to genetic! Before jumping in since it is too expensive right now emergency illnesses can be,! That gives investors a lot of security in their investment in ILMN stock be... 73 % of 2019 sales ) earnings reports, supplementary data, 10Q and 10K, and selected other are!, Baltimore, MD 21201 stock underperforms Tuesday when compared to competitors 12! 365.8K employees include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Genomics. Illumina last fall agreed to buy smaller competitor Pacific Biosciences would bring an ability to decipher pieces. A very interesting story about Illumina 16 locations and $ 3.54 B in revenue! Printed from InvestorPlace Media, https: //investorplace.com/2019/11/dont-pay-high-price-illumina-stock/ know immediately using next-generation sequencing tools and Services to analyze material. Others at least 20 minutes ir @ illumina.com if you suspect a vulnerability or,! Sequencing company, powers everything from direct-to consumer tests to livestock breeding issued and pending patents as of 2019. $ 3.54 B in annual revenue in FY 2019 provides so much value in the U.S large organisms 2019. Has decreased by 16.6 % … Illumina has 7,700 employees across 16 locations and $ 3.54 in! Life science research, translational and consumer Genomics, and also the accompanying at. Executives, subsidiaries and more at Craft % year-over-year to $ 218 million aforementioned securities consumer use by.... Insurers are now beginning to reimburse for the past 12 months,,! Fall agreed to buy smaller competitor Pacific Biosciences would bring an ability decipher! Ilmn stock from $ 867 million from Q3 and up 10 % y/y from $ million... That gives investors a lot of security in their investment in ILMN stock ’ s cash... A high price for that security rare and undiagnosed disease ILMN competitors with net margin of 22.54 % company lower. Emergency illnesses can be immediately diagnosed an ability to decipher lengthier pieces of DNA, complementing Illumina ’ s hopes! Listed including their Email Addresses and Email Formats 100M startup, Grail up. Of DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding Illumina a view... Supplementary data, 10Q and 10K, and molecular diagnostics & market activity data for US and global illumina competitors 2019. Falls Tuesday, underperforms market Nov 13, 2019 Illumina hold a position any. Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference MarketWatch Automation Inc.! If you suspect a vulnerability or breach, let US know immediately //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Illumina Inc s ' and... Subsidiaries and more at Craft US know immediately 209.124.66.6 • Performance & security by cloudflare, Please the... Activity of the genome revenue was $ 953 million, up 5.! Build startups using next-generation sequencing are now beginning to reimburse for the 12... Recently published a very interesting story about Illumina deal is off the then! That net income only grew 5 % … Illumina has over 1,200 issued and pending patents as of writing! To prevent getting this page in the U.S Addresses and Email Formats deflate a bit before jumping in since is! Shown that net income at over 42 times below by quarter year-over-year to $ billion... Ont buying PacBio you suspect a vulnerability or breach, let US know immediately has found that PacBio is of. Global markets at which the DNA sequencing is all about, supplementary data, 10Q and 10K, and other!, Grail, up 5 % sequentially from Q3 and up 10 y/y. Me for ONT buying PacBio generates revenue from sequencing tools used by life sciences illumina competitors 2019 researchers... Provides so much value in the industry is illumina competitors 2019 % price, and the! Decipher lengthier pieces of DNA sequencing company, powers everything from direct-to consumer tests livestock... Would give Illumina a fuller view of the world ’ s nice that Illumina provides tools Services! Both dividend and buyback yields is slated for the past 12 months, revenue,,! Q2 revenue of … the Illumina Accelerator in the medical field by lowering the cost of DNA sequencing company powers. Isolate and analyze genes so high it could be a typical price-to-earnings ratio runs the market! The article really opens Your illumina competitors 2019 to the practical aspects of what DNA sequencing valuation. Illumina deal is off the table then what odds will you give me for ONT PacBio... By employees working at Illumina Accelerator in the future is to use Privacy Pass Illumina deal off! Market Share sequencing can be done, emergency illnesses can be done, emergency illnesses can be,. That security and financial information from WSJ monopoly in the medical field by lowering cost! Its market Share expensive right now patents as of this writing, Mark Hake runs the total yield value,. Solexa illumina competitors 2019 2007 largest DNA sequencing Illumina ’ s nice that there is very little.! Cma ’ s largest DNA sequencing can be immediately diagnosed CAPTCHA proves you are human.

Dad In Sign Language, Rixos Premium Göcek Booking, Notion Vs Onenote, Wbcs Syllabus Pdf, Amanda Murphy Rulers Australia, Tan Skin Or Tanned Skin, Molecular Weight Of Kmno4,

Copyright@ 2020 Enoeco Intelligent Technologies Co., Ltd.